Stay updated with breaking news from Gray Cap. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
105 million 30 µg, 10 µg and 3 µg doses to be delivered into Q4 2022, with an option for the U.S. Government to purchase up to 195 million additional doses Pfizer Inc. (NYSE: PFE) and BioNTech
Omicron-adapted monovalent candidate given as a fourth booster dose elicited a 13.5 and 19.6-fold increase in neutralizing geometric titers against Omicron BA.1 at 30 µg and 60 µg dose levels; bivalent
In a Phase 2/3 clinical trial, the Pfizer-BioNTech COVID-19 Vaccine elicited a strong immune response in this age group Three 3-µg doses had favorable safety profile similar to placebo in
A copy of an internal email data May 25, 2022, suggests that the United States military is not operating above-board when it comes to administering Wuhan coronavirus (Covid-19) [...]
EUA is based on data that show children 5 through 11 years of age had a robust immune response with a favorable safety profile following a 10-µg booster dose of the Pfizer-BioNTech COVID-19 Vaccine